Cabaletta Bio, Inc. (CABA) stock
CABANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.28−0.05 (-3.76%)
Close on Nov 13, 2026Market cap $217.02MP/E –Yield –
Cabaletta Bio r&d expenses
Research and development expenses are spending on new products and technology.
Cabaletta Bio's R&D Expenses for the twelve months ending Sep 30, 2026 was $165.12M, up 25.1% year over year. For fiscal 2025 it was $142.67M, up 46.8% from the year before. The highest annual figure on record is $142.67M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.67M | +46.8% |
| FY2024 | Dec 31, 2024 | $97.20M | +75.4% |
| FY2023 | Dec 31, 2023 | $55.42M | +41.0% |
| FY2022 | Dec 31, 2022 | $39.30M | +20.9% |
| FY2021 | Dec 31, 2021 | $32.49M | +52.0% |
| FY2020 | Dec 31, 2020 | $21.38M | +83.2% |
| FY2019 | Dec 31, 2019 | $11.67M | +161.3% |
| FY2018 | Dec 31, 2018 | $4.47M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $47.14M | +18.4% |
| Q2 FY2026 | Jun 30, 2026 | $44.43M | +18.0% |
| Q1 FY2026 | Mar 31, 2026 | $37.35M | +28.7% |
| Q4 FY2025 | Dec 31, 2025 | $36.19M | +41.8% |
| Q3 FY2025 | Sep 30, 2025 | $39.82M | +51.5% |
| Q2 FY2025 | Jun 30, 2025 | $37.64M | +60.7% |
| Q1 FY2025 | Mar 31, 2025 | $29.02M | +32.2% |
| Q4 FY2024 | Dec 31, 2024 | $25.53M | +46.7% |
| Q3 FY2024 | Sep 30, 2024 | $26.29M | +90.7% |
| Q2 FY2024 | Jun 30, 2024 | $23.43M | +98.6% |
| Q1 FY2024 | Mar 31, 2024 | $21.95M | +76.6% |
| Q4 FY2023 | Dec 31, 2023 | $17.41M | +40.4% |
| Q3 FY2023 | Sep 30, 2023 | $13.79M | +67.8% |
| Q2 FY2023 | Jun 30, 2023 | $11.80M | +24.0% |
| Q1 FY2023 | Mar 31, 2023 | $12.44M | +35.6% |
| Q4 FY2022 | Dec 31, 2022 | $12.40M | +25.0% |
| Q3 FY2022 | Sep 30, 2022 | $8.22M | +0.6% |
| Q2 FY2022 | Jun 30, 2022 | $9.51M | +21.2% |
| Q1 FY2022 | Mar 31, 2022 | $9.17M | +39.9% |
| Q4 FY2021 | Dec 31, 2021 | $9.92M | +71.8% |
| Q3 FY2021 | Sep 30, 2021 | $8.17M | +44.6% |
| Q2 FY2021 | Jun 30, 2021 | $7.85M | +47.3% |
| Q1 FY2021 | Mar 31, 2021 | $6.56M | +41.9% |
| Q4 FY2020 | Dec 31, 2020 | $5.78M | +90.8% |
| Q3 FY2020 | Sep 30, 2020 | $5.65M | +75.5% |
| Q2 FY2020 | Jun 30, 2020 | $5.33M | +100.1% |
| Q1 FY2020 | Mar 31, 2020 | $4.62M | +67.3% |
| Q4 FY2019 | Dec 31, 2019 | $3.03M | +144.2% |
| Q3 FY2019 | Sep 30, 2019 | $3.22M | +24.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.66M | – |
| Q1 FY2019 | Mar 31, 2019 | $2.76M | – |
| Q4 FY2018 | Dec 31, 2018 | $1.24M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.59M | – |
See a number that looks wrong?